Immune Regulation News 10.25 July 6, 2018 | |
| |
TOP STORYThe Purinergic Receptor P2RX7 Directs Metabolic Fitness of Long-Lived Memory CD8+ T Cells Investigators showed that P2RX7 was required for the establishment, maintenance and functionality of long-lived central and tissue-resident memory CD8+ T cell populations in mice. [Nature] Abstract | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)Scientists found that deletion of regulatory factor X 7 (Rfx7) leads to a decrease in natural killer (NK) cell maintenance and immunity in vivo. Genomic approaches showed that Rfx7 coordinated a transcriptional network controlling cell metabolism. [Nat Immunol] Abstract A Synthetic Cross-Species CD200R1 Agonist Suppresses Inflammatory Immune Responses In Vivo The CD200R1 DNA aptamer CCS13 displayed the highest agonistic activity toward CD200R1 in terms of suppressing the induction of cytotoxic T-lymphocytes in both human and murine allogeneic-mixed lymphocyte cultures. [Mol Ther Nucleic Acids] Full Article The Methyltransferase PRMT6 Attenuates Antiviral Innate Immunity by Blocking TBK1-IRF3 Signaling Researchers performed a functional screen of the nine mammalian protein arginine methyltransferases (PRMTs) for regulators of IFN-β expression and found that PRMT6 inhibits the antiviral innate immune response. Viral infection also upregulated PRMT6 protein levels. [Cell Mol Immunol] Abstract The authors identified fish miR-210 as a robust regulator involved in regulating virus-host interactions. They found that rhabdovirus significantly upregulated the expression of fish miR-210. [J Immunol] Abstract Scientists showed that a supramolecule assembly homes onto signal regulatory protein alpha (SIRPα) on macrophages, blocking the CD47-SIRPα signaling axis while sustainedly inhibiting CSF-1R. [Nat Biomed Eng] Abstract | Press Release In the murine burn injury model, CD4+ Treg activation pathways were selectively addressed using TNFR2-, toll like receptor-4 (TLR4)- and IL-10-deficient mice. The CD4+ Treg signaling molecule PKC-θ was analyzed using phospho-flow cytometry to detect rapid cell activation. [Cell Immunol] Abstract Researchers demonstrated tumor immune escape mechanisms that suppress CD8+ T cells cytotoxicity. CD8+ T cells from peripheral blood, sentinel nodes, and tumor were analyzed in steady state and in vitro-stimulated conditions by flow cytometry, RT-qPCR, and ELISA. [PLoS One] Full Article Scientists uncovered a novel mechanism that may explain how MCPIP1 efficiently inhibits IFNβ innate immune. It was found that MCPIP1 negatively regulates the IFNβ expression activated by RIG-I, STING, TBK1, IRF3. [Biochem Biophys Res Commun] Abstract Subscribe to our sister publications: Human Immunology News & Immunology of Infectious Disease News. | |
| |
REVIEWSTissue-Specific Functions of Invariant Natural Killer T Cells The authors summarize the functions of invariant natural killer T cells (iNKT) cells in four tissues in which they are prevalent, namely, the liver, the lungs, adipose tissue and the intestine. They explain how local iNKT cell responses at each site contribute to tissue homeostasis and protection from infection but can also contribute to tissue inflammation and damage. [Nat Rev Immunol] Abstract MicroRNA miR-223 as Regulator of Innate Immunity Investigators summarize several topics covering the function of miR-223 in myeloid differentiation, neutrophil and macrophage functions, as well as in inflammatory diseases including acute respiratory distress syndrome and inflammatory bowel disease. [J Leukoc Biol] Abstract Visit our reviews page to see a complete list of reviews in the immune regulation research field. | |
| |
INDUSTRY NEWSKymab Group Ltd announced a clinical trial agreement with F. Hoffmann-La Roche Ltd. Under the agreement, Roche will provide its PD-L1 blocking antibody atezolizumab for use in combination in Kymab’s upcoming Phase I-II clinical studies combining its lead investigational anti-ICOS antibody therapy KY1044 in patients with advanced solid cancers. [Kymab Group Ltd] Press Release InflaRx N.V. announced the approval of their Investigational New Drug (IND) application by the FDA. [InflaRx N.V.] Press Release Neovacs announced the results of its Phase IIb clinical trial of IFNα Kinoid in patients with moderate to severe lupus. [Neovacs] Press Release Compugen Welcomes FDA Clearance of Bayer’s IND Application for BAY 1905254 Compugen Ltd. was informed that the FDA has cleared Bayer AG’s investigational new drug (IND) application for BAY 1905254, a first-in-class immuno-oncology therapeutic antibody targeting the ILDR2 protein in patients with advanced solid tumors. [Compugen, Ltd.] Press Release Sorrento Therapeutics, Inc. announced that it acquired the Sofusa™ lymphatic delivery technology platform from Kimberly-Clark Corporation for targeted biopharmaceuticals, particularly, the immune checkpoint inhibitors and other I-O antibodies. [Sorrento Therapeutics, Inc.] Press Release | |
| |
POLICY NEWSControversial CRISPR ‘Gene Drives’ Tested in Mammals for the First Time A controversial technology capable of altering the genomes of entire species has been applied to mammals for the first time. In a preprint posted to bioRxiv on 4 July, researchers describe developing ‘gene drives’ — which could be used to eradicate problematic animal populations — in lab mice using the CRISPR gene-editing technique. [Nature News] Editorial The country is making a serious investment in becoming a world-class science superpower. [Scientific American] Editorial Hidden Conflicts? Pharma Payments to FDA Advisers after Drug Approvals Spark Ethical Concerns In examining compensation records from drug companies to physicians who advised FDA on whether to approve 28 psychopharmacologic, arthritis, and cardiac or renal drugs between 2008 and 2014, Science found widespread after-the-fact payments or research support to panel members. The agency’s safeguards against potential conflicts of interest are not designed to prevent such future financial ties. [ScienceInsider] Editorial A Better Measure of Research from the Global South Funders Jean Lebel and Robert McLean describe a new tool for judging the value and validity of science that attempts to improve lives. [Nature News] Editorial
| |
EVENTSNEW Keystone Symposia: B Cell-T Cell Interactions Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Postdoctoral Researcher – T Cell Biology (Washington University School of Medicine) Research Technologist – Cell Separation (STEMCELL Technologies Inc.) Professorship – Molecular Immune Regulation (Kiel University) Postdoctoral Fellowships – Immunometabolism (St. Jude Children’s Research Hospital) Assistant/Associate Professor – Immunology (University of Massachusetts) PhD Student – Cellular Immunotherapy (Glycostem Therapeutics) PhD Student Positions – Immunology (Multiple Locations) Postdoctoral Research Scientist – Immunology (Lilly) Postdoctoral Fellowship – Immunology (University of South Carolina) Postdoctoral Fellow – Immunology (Boston University School of Medicine) Postdoctoral Fellow – Innate Immune Signaling (Houston Methodist Research Institute) Postdoctoral Associate Position – Tumor Immunology/Immunotherapy (Duke Cancer Institute) Assistant, Associate, or Full Member – Cancer Immunology (Fred Hutchinson Cancer Research Center) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Immune Regulation News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|